logo-loader

Outlook Therapeutics' wet AMD therapy study results validates expectations, looks forward to Phase 3

Published: 13:43 31 Aug 2020 EDT

Outlook Therapeutics, Inc. (NASDAQ:OTLK) CEO Lawrence Kenyon tells Proactive the clinical-stage biopharmaceutical company says its ONS-5010 therapy to treat wet AMD revealed positive proof-of-concept results.

Kenyon says investors should understand that this small, 60-patient clinical study was not expected to achieve statistical significance, however, its pivotal NORSE 2 pivotal trial will reveal these results.

Outlook Therapeutics reaches another milestone with FDA acceptance of wet...

Outlook Therapeutics Inc (NASDAQ:OTLK) President and CEO Russ Trenary tells Proactive's Stephen Gunnion that the company faces the most significant milestone in its history if the US Food and Drug Administration (FDA) approves its investigational ophthalmic formulation for treating wet...

on 11/03/2022